Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Ayala Pharmaceuticals, Inc. | d35890dex322.htm |
| EX-31.2 - EX-31.2 - Ayala Pharmaceuticals, Inc. | d35890dex312.htm |
| EX-31.1 - EX-31.1 - Ayala Pharmaceuticals, Inc. | d35890dex311.htm |
| 10-Q - 10-Q - Ayala Pharmaceuticals, Inc. | d35890d10q.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Ayala Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: November 16, 2020 | By: | /s/ Roni Mamluk | ||||
| Roni Mamluk, Ph.D. | ||||||
| President and Chief Executive Officer | ||||||
| (principal executive officer) |